03:05 PM EST, 03/08/2024 (MT Newswires) -- Novo Nordisk ( NVO ) said Friday it has received approval from the US Food and Drug Administration for Wegovy's expanded indication to reduce cardiovascular risks in adults with overweight or obesity and established cardiovascular disease.

The approval was based on the Select cardiovascular outcomes trial that showed Wegovy significantly reduced the risk of major adverse cardiovascular events by 20% versus placebo when added to the standard of care, the drugmaker said.

Novo Nordisk ( NVO ) said it also filed for a label expansion in the European Union, with a decision expected this year.

Price: 133.25, Change: -2.67, Percent Change: -1.96